Zydus Cadila gets USFDA nod for generic epilepsy drug
New Delhi: Drug firm Zydus Cadila has received the US health regulators nod to market Felbamate tablets, used to treat seizures in people with epilepsy, in the American market.
The company has received approval from the US Food and Drug Administration (USFDA) to market the drug in strengths of 400 mg and 600 mg, Zydus Cadila said in a statement.
Felbamate is an oral drug used to treat seizures in people with epilepsy.
The company will manufacture the drug at its plant in Ahmedabad.
The Gujarat group has more than 115 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since it commenced filings in 2003-04.
Shares of companys listed entity Cadila Healthcare ended 1.23 per cent down at Rs 464.55 on BSE.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd